Last updated on October 2018

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)


Brief description of study

This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus sitagliptin 100 mg once-daily on glycaemic control after 30 weeks of treatment. Subjects will remain on their stable pre-trial metformin.

Clinical Study Identifier: NCT03061214

Contact Investigators or Research Sites near you

Start Over

Novo Nordisk

Novo Nordisk Investigational Site
Daejeon, Korea, Republic of